Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 26;5(5):e564. doi: 10.1097/HS9.0000000000000564

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

PMC Copyright notice

Figure 2. — Schematic representation of the analysis 265 biomarkers in plasma from patients with CLL before and after treatment with ibrutinib. Biomarkers were subdivided into CLL-associated and CLL nonassociated (left) and were further assembled into CD markers and other families of proteins (right). Only 12/86 markers increased, 8 of which were cardiovascular-related, and indicative of “off-target” effects. Among the 86 biomarkers, 4 do not belong to either the CLL-associated, or CLL nonassociated biomarkers, IFNLR1, IL-12B, TXLNA, and SEZ6L, but are indicatively downregulated. Among the 2 categories CD-marker and other protein families (right) some of these biomarkers belong to both groups. CLL = chronic lymphocytic leukemia.